ClinicalTrials.gg
RecruitingNCT06385067Updated Oct 27, 2026

Treatment of Primary Coronary Artery Vascular Lesions With Biolimus Coated Coronary Balloon Dilation Catheter

An observational study in Coronary Artery Disease, sponsored by JW Medical Systems Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by JW Medical Systems Ltd (part of Blue Sail Medical Co., Ltd.) · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Oct 27, 2026Now RecruitingFirst site in China+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. — 8 open to participants now, 11 under way, none of them phase 3. Coronary Artery Disease · Blue Sail Medical Co., Ltd..

Started
2024
with 4 others
Observational
7 of 23
1 open now
Primary completion
2025-12
later than 5 of 10 live
Registered
19th of 23
by date

Among the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., this one is one of 5 that started in 2024, is one of 7 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 19th registered.

Coronary Artery Disease

4,865 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

8 of the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., or all of them as a file.
02

Study summary

The purpose of the study was to further evaluate the long-term safety and efficacy of the Biolimus Coated Coronary Artery Balloon Dilation Catheter in the real world.

The study population was patients with primary coronary vascular lesions with a blood vessel diameter of 2.0mm-2.75mm.

Read the detailed description

Study Design:

  1. Prospective, international multi-center clinical study;
  2. It is planned to recruit 300 subjects in China and a total of 100 subjects in Indonesia and Thailand who meet the criteria for study inclusion to use at least one Biolimus coated coronary balloon dilation catheter (BioAscend) to treat primary in situ coronary artery vascular disease with a diameter of 2.0mm-2.75mm regardless of the number of blood vessels, the length and number of treated lesions;
  3. In the study, subgroups of long lesions, bifurcation lesions, and acute myocardial infarction were set up, and subjects who met the definition were directly entered into the subgroup analysis.
  4. Register and collect data using the EDC system;
  5. Enrollment method: competitive enrollment;
  6. Follow-up time points: postoperative to before discharge, 30 days, 6 months, 12 months, and 24 months.
03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Recruit 300 subjects in China and a total of 100 subjects in Indonesia and Thailand who meet the criteria for study inclusion to use at least one Biolimus coated coronary balloon dilation catheter (BioAscend) to treat primary in situ coronary artery vascular disease with a diameter of 2.0mm-2.75mm regardless of the number of blood vessels, the length and number of treated lesions;

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years;
  • Primary coronary artery stenosis with a vessel diameter of 2.0 mm to 2.75 mm;
  • Patients with residual stenosis of ≤ 30 percent after pretreatment and ≤ type B dissection; Patients who voluntarily participate in and sign the form, and who are willing to undergo follow-up as required by the protocol.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females;
  • Patients with cardiogenic shock;
  • Patients with severe congestive heart failure or severe heart failure with class IV;
  • Patients with severe valvular heart disease;
  • Patients with a of less than 24 months or factors that make clinical follow-up difficult;
  • Patients who are considered unsuitable for inclusion by the investigator for other reasons.
  • Those who are known to be allergic to melcrolimus and contrast media.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Experimental group

    Use at least one Biolimus coated coronary balloon dilation catheter (BioAscend) to treat primary in situ coronary artery vascular disease with a diameter of 2.0 mm-2.75 mm regardless of the number of blood vessels, the length and number of treated lesions.

    Device: Biolimus Coated Coronary Artery Balloon Dilation Catheter

Interventions

  • DeviceBiolimus Coated Coronary Artery Balloon Dilation Catheter

    Patients with Coronary Artery Disease will be treated with Biolimus Coated Coronary Artery Balloon Dilation Catheter

06

What researchers measure

Primary outcomes

  1. Target lesion failure rate (TLF)

    Target lesion failure rate (TLF) at 12 months after surgery, including cardiogenic death, target vascular myocardial infarction, and clinically symptom-driven target lesion revascularization (CD-TLR)

    Time frame: 12 months after surgery

Secondary outcomes

  1. Interventional success rate

    Including device success rate, pathogenic power and clinical success rate

    Time frame: Immediately after operation

  2. Device-related cardiovascular clinical composite endpoint

    Device-related cardiovascular clinical composite endpoints from postoperative to pre-discharge, day 30, month 6, month 12, and month 24, including cardiac death, target vessel myocardial infarction, and clinically symptom-driven target lesion revascularization (excluding elective interventional therapy)Device-related cardiovascular clinical composite endpoints from postoperative to pre-discharge, day 30, month 6, month 12, and month 24, including cardiac death, target vessel myocardial infarction, and clinically symptom-driven target lesion revascularization (excluding elective interventional therapy)

    Time frame: From postoperative to before discharge, day 30, month 6, month 12, month 24

  3. Patient-related cardiovascular clinical composite endpoint

    Patient-related cardiovascular clinical composite endpoints including all-cause mortality, all myocardial infarction, and any revascularization (excluding elective interventional therapy) from postoperative to pre-discharge, day 30, month 6, month 12, and month 24

    Time frame: From postoperative to before discharge, day 30, month 6, month 12, month 24

  4. Major adverse cardiac events (MACEs)

    Including cardiac death, myocardial infarction, and target lesion revascularization (TLR) at postoperative to pre-discharge, day 30, month 6, month 12, and month 24.

    Time frame: From postoperative to before discharge, day 30, month 6, month 12, month 24

  5. Incidence of thrombotic events as defined by ARC

    Including identified, probable, and unexcluded thrombosis in the acute, subacute, and late periods acute, subacute, and late Defined, probable, and non-excluded thrombosis within the segment

    Time frame: From postoperative to before discharge, day 30, month 6, month 12, month 24

07

Study locations

2 of 2 sites recruiting
  • The First People's Hospital of Lanzhou
    Lanzhou, Gansu, China
    Recruiting
    • Doctor · Contact
  • the First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi, China
    Recruiting
    • Professor Li Lang, Doctor · Contact0771-5356566
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Dec 2025, 19 months.

Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's 19 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
Apr 25, 2024
StartActual
May 10, 2024
Primary completionActual
Dec 30, 2025
CompletionEst.
Dec 30, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
2 sites added — first site in China
Show 2 added (2 China)
  • The First People's Hospital of Lanzhou · Lanzhou, China
  • the First Affiliated Hospital of Guangxi Medical University · Nanning, China
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in China
    Show 2 added (2 China)
    • The First People's Hospital of Lanzhou · Lanzhou, China
    • the First Affiliated Hospital of Guangxi Medical University · Nanning, China
    + 4 other changes: verification date, date precision, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06385067
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
May 10, 2024
Primary completion
Dec 30, 2025
Completion
Dec 30, 2026 (estimated)
Last update
Oct 27, 2026

Study contacts

Yuanchun Sun
Contact
sunyuanchun@bluesail.cn
13683382463
Lang Li
principal investigator · First Affiliated Hospital of Guangxi Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion